US 11,701,357 B2
Treatment of B cell cancers using a combination comprising Btk inhibitors
Nan Hu, Beijing (CN); Lai Wang, Beijing (CN); Jing Song, Beijing (CN); Tong Zhang, Beijing (CN); Kang Li, Beijing (CN); Lusong Luo, Beijing (CN); Min Wei, Beijing (CN); Zhiwei Wang, Beijing (CN); and Yunhang Guo, Beijing (CN)
Assigned to BEIGENE SWITZERLAND GMBH, Basel (CH)
Appl. No. 16/326,467
Filed by BeiGene Switzerland Gmbh, Basel (CH)
PCT Filed Aug. 18, 2017, PCT No. PCT/CN2017/098023
§ 371(c)(1), (2) Date Feb. 19, 2019,
PCT Pub. No. WO2018/033135, PCT Pub. Date Feb. 22, 2018.
Claims priority of application No. PCT/CN2016/096082 (WO), filed on Aug. 19, 2016.
Prior Publication US 2021/0275530 A1, Sep. 9, 2021
Int. Cl. A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] 19 Claims
 
1. A method for the delay of progression or treatment of a B cell cancer in a subject, comprising administering to the subject in need thereof (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof, at a dose of 320 mg once a day (QD) or 160 mg twice a day (BID) in 28-day cycles, in combination with obinutuzumab administered by three loading doses of 1000 mg weekly followed by 1000 mg on day one of cycles 2-6, wherein the subject is a human.